

30 JANUARY 2026

ASX RELEASE

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – DECEMBER 2025

Key Highlights from the Quarter

- **ACCENT Trial Success:** The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapy
- **AMPLICITY Trial Initiation:** The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruitment is ongoing in Melbourne and Sydney with US sites planned to open imminently
- **Regulatory and Commercial Developments:** Positive FDA feedback on dose optimization was received; a key patent for narmafotinib was granted; and Amplia successfully uplisted to the US-based OTCQB Venture Market, enhancing its investor reach
- **Preclinical Studies:** The second phase of a research program evaluating the activity of narmafotinib in patient-derived pancreatic cancer cells carrying specific genetic mutations has been initiated

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is announces further clinical and preclinical progress across its small molecule, focal adhesion kinase (FAK) inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 31 December 2025.

Operations Update

Amplia continues to progress the clinical development of narmafotinib, the Company’s best-in-class FAK inhibitor, for the treatment of metastatic pancreatic cancer in two clinical trials. This quarter the Company has reported updated results from the ACCENT trial, as well as important progress in regulatory interactions, intellectual property, investor outreach and preclinical studies.

Clinical Trial Updates

The ACCENT clinical trial is investigating the combination of narmafotinib with standard-of-care chemotherapies gemcitabine and Abraxane®. The Company announced additional confirmed partial responses (PRs) in October, and subsequently December, bringing the overall response rate for the trial to 35% (19 PRs out of 55 patients). A confirmed partial response (PR) is defined as tumour shrinkage exceeding 30%, sustained for at least two months and without the appearance of new cancerous lesions. This ORR (Objective Response Rate) is a considerable improvement over the 23% response rate reported

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com

Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

for chemotherapy alone in the clinical study on which we have benchmarked the ACCENT trial¹. Combining both confirmed and unconfirmed responses leads to a response rate of 42%.

In the October release², the Company also reported that the mean duration on trial (a key indicator of the drug combination's ability to halt cancer progression) was calculated at 219 days from a data cut-off of 25 September. This is substantially better than typically seen for chemotherapy alone. Significantly, at this time seven patients had remained on the study for at least 12 months, and two patients had continued for more than 18 months.

Importantly the combined clinical data continues to show that narmafotinib is generally well tolerated by patients. The adverse event profile for the narmafotinib combination closely mirrors that of the chemotherapy regimen with no other significant toxicities reported.

AMPLICITY Trial

Amplia has begun the Phase 1b/2a AMPLICITY clinical trial, where the combination of narmafotinib with FOLFIRINOX chemotherapy is being investigated. FOLFIRINOX, a more aggressive chemotherapy treatment, is widely used in the treatment of advanced pancreatic cancer in the US and Western Europe. This open-label trial aims to identify the optimal daily dose of narmafotinib, given orally, when paired with FOLFIRINOX, which is administered intravenously every two weeks. Patient recruitment has commenced at sites in Melbourne and Sydney. Five clinical sites, at highly respected tertiary institutions, have been identified and are in the final stages of contracting. Our expectation is these will open in the coming months.

Regulatory and Commercial Progress

This quarter, the Company announced that it had received positive feedback from the US FDA supporting the dose optimisation strategy for narmafotinib in its planned registration enabling Phase 2b/3 trial in pancreatic cancer. Proposed amendments to the trial design are not expected to impact the overall development timeline.

The Company also announced that a key patent covering the specific salt and crystal form of narmafotinib used in clinical trials was granted by the US Patent and Trade Marks Office. The patent extends protection of the developed form of narmafotinib out to at least 2040 in the US and the other jurisdictions (including Europe, Japan, India and Australia) where the patent has been granted.

Amplia also announced this quarter successful completion of the uplisting to the US-based OTCQB. The OTCQB Venture Market is a U.S. trading platform operated by OTC Markets Group where U.S.-based investors can trade in Amplia Therapeutics' common stock in U.S. dollars during U.S. market hours, while the Company maintains its primary listing on the ASX via codes ATX and ATXOA.

Preclinical Studies

In December, Amplia announced that it had advanced into a second phase of its research collaboration with specialty Korean biotech *Next & Bio*, following a successful initial program that produced encouraging early data. The collaboration focuses on evaluating Amplia's FAK inhibitors against patient-derived pancreatic cancer cells carrying specific genetic mutations present in over 90% of pancreatic cancer cases.

Future Outlook

Over the coming months mature data will become available from the ACCENT trial, whilst progress with the AMPLICITY trial will also be announced. Additional preclinical data, including from the *Next & Bio* collaboration, will also be disclosed demonstrating new opportunities for narmafotinib in the treatment of pancreatic and other cancers.

¹ *New England Journal of Medicine* 2013; 369: 1691 – 703

² ASX Release 09 October 2025

Financial update

Amplia finished the December 2025 quarter with a cash position of \$31.5 million (September 2025: \$29.2 million). During the quarter, the Company had net operating cash inflows of \$2.4 million in relation to operating activities (September 2025: \$3.8 million outflows). Operating cashflows included:

- Inflows of \$3.8 million from government grants and tax incentives;
- Outflows of \$0.9 million for staff and administration/corporate costs; and
- Outflows of \$0.9 million for research and development costs, which primarily related to trial costs, Contract Research Organisation (CRO), manufacturing and other CMC related costs incurred in relation to the ACCENT Phase 2 clinical trial for narmafotinib with gemcitabine and Abraxane® and for its AMPLICITY clinical trial for narmafotinib combined with FOLFIRINOX.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, salaries and superannuation. Total payments made for the quarter equals \$112,500 and relate to payments to the CEO/Managing Director in line with employment contracts and payments to the Non-Executive Directors.

- End -

For Further Information

Dr. Christopher Burns
CEO and Managing Director

Chris@ampliatx.com
www.ampliatx.com

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the **ACCENT** trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.6 months has also been reported. A second trial – **AMPLICITY** – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AMPLIA THERAPEUTICS LIMITED

ABN

16 165 160 841

Quarter ended ("current quarter")

31 December 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(908)	(6,496)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(381)	(1,293)
(f) administration and corporate costs	(528)	(1,644)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	268	424
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	3,784	3,784
1.8 Other (payment of GST)	207	24
1.9 Net cash from / (used in) operating activities	2,442	(5,201)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(2)	(28)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (bank guarantee and security deposit)	-	(64)
2.6	Net cash from / (used in) investing activities	(2)	(92)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	27,647
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	238
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(49)	(1,858)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	(27)	(59)
3.10	Net cash from / (used in) financing activities	(76)	25,968

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	29,156	10,863
4.2	Net cash from / (used in) operating activities (item 1.9 above)	2,442	(5,201)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(92)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(76)	25,968
4.5	Effect of movement in exchange rates on cash held	(23)	(41)
4.6	Cash and cash equivalents at end of period	31,497	31,497

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,261	2,428
5.2	Call deposits	29,236	26,728
5.3	Bank overdrafts	-	-
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	31,497	29,156

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	113
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

The amount at 6.1 includes Director fees and salary (including superannuation) for the CEO and Managing Director and Non-Executive Directors.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	2,442
8.2	Cash and cash equivalents at quarter end (item 4.6)	31,497
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	31,497
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

30 January 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.